Parathyroid hormone (1-34) (human): Mechanistic Precision for Bone and Kidney Research

Executive Summary. Parathyroid hormone (1-34) (human) is a synthetic peptide fragment representing the bioactive region of the native hormone, central to calcium homeostasis and PTH/PTHrP receptor signaling (APExBIO). Its sub-nanomolar potency as a parathyroid hormone 1 receptor agonist has been established in cAMP assays (IC₅₀ = 0.22 nM, 293 cells) (Huang et al., 2025). The peptide's mechanistic roles in bone formation, renal calcium reabsorption, and inositol phosphate synthesis are quantitatively characterized. High-purity lots (>97.8%) are available for reproducible experimental workflows. Integration into advanced kidney assembloid and osteoporosis models has expanded its translational reach (see comparison).

Biological Rationale

Parathyroid hormone (1-34) (human) is a truncated peptide fragment containing the first 34 amino acids of human parathyroid hormone, sequence: H₂N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH. It retains all the receptor-binding and bioactive domains necessary for functional mimicry of the full-length hormone (APExBIO). This peptide is secreted physiologically by chief cells in the parathyroid gland and is a critical regulator of extracellular calcium and phosphate levels. Its action is indispensable for maintaining skeletal integrity and mineral ion balance. The PTH (1-34) fragment specifically targets tissues expressing parathyroid hormone receptors (PTH1R and PTH2R), with highest expression in bone and kidney. It is a reference standard for dissecting calcium homeostasis and bone remodeling processes in basic and translational research (see extension: advanced cAMP signaling insights).

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) (human) binds to the parathyroid hormone 1 receptor (PTH1R) and, to a lesser extent, PTH2R, both G protein-coupled receptors. Receptor engagement activates two main intracellular cascades:

• cAMP Signaling Pathway: Binding stimulates adenylyl cyclase, elevating intracellular cAMP levels. In human embryonic kidney 293 cells transfected with PTH1R, the peptide displays an IC₅₀ of 0.22 nM for cAMP production (Huang et al., 2025, Table S2).
• Inositol Phosphate Synthesis: The hormone also triggers phospholipase C activation, increasing inositol trisphosphate (IP₃) and diacylglycerol (DAG) generation, which modulate calcium mobilization and downstream gene expression.

Systemic Outcomes: PTH (1-34) enhances bone resorption (liberating Ca²⁺), increases renal calcium and magnesium reabsorption in distal tubules and the thick ascending limb, and promotes intestinal calcium absorption via upregulation of 1,25-dihydroxyvitamin D synthesis (see mechanistic deep dive). These actions are tightly regulated and dose-dependent.

Evidence & Benchmarks

• PTH (1-34) (human) stimulates cAMP accumulation in PTH1R-expressing 293 cells with an IC₅₀ of 0.22 nM at 37°C in HBSS buffer (Huang et al., 2025, DOI).
• Subcutaneous dosing in male Fisher 344 rats (10 or 40 μg/kg/day for 4 weeks) increases trabecular and cortical bone mass, confirmed by histomorphometry and DXA scans (APExBIO).
• In kidney assembloid models, PTH (1-34) supports the maturation of nephron structures and functional responses related to calcium handling (Huang et al., 2025, DOI).
• The peptide is highly soluble in DMSO (≥399.3 mg/mL) and water (≥19.88 mg/mL), but insoluble in ethanol, facilitating diverse assay formats (APExBIO).
• Purity exceeds 97.8% by HPLC and MS, ensuring reliable performance in cell-based and in vivo assays (APExBIO).

Applications, Limits & Misconceptions

PTH (1-34) (human) is widely used in:

• Bone Metabolism Research: Standard agent for modeling osteoporosis, bone turnover, and evaluating anabolic versus catabolic skeletal responses.
• Kidney Disease Modeling: Integrated into human kidney assembloid and organoid systems for dissecting calcium transport and hormone-receptor interactions (Huang et al., 2025).
• Signal Transduction Studies: Reference agonist for cAMP and inositol phosphate pathway mapping.

For comparison, prior reviews (see best practices) focused on cell viability and protocol tips; this article extends to disease modeling and translational application benchmarks.

Common Pitfalls or Misconceptions

• Misconception: PTH (1-34) is suitable for diagnostic/therapeutic use. Clarification: It is strictly for research (APExBIO).
• Misconception: Ethanol is a viable solvent for PTH (1-34). Clarification: The peptide is insoluble in ethanol.
• Misconception: Solutions can be stored long-term without degradation. Clarification: Use freshly prepared aliquots; storage at -20°C in desiccated form is required for stability.
• Boundary: The peptide does not recapitulate all full-length hormone functions, such as N-terminal-independent signaling.
• Boundary: In vitro kidney organoids may not fully replicate adult renal physiology—see Huang et al., 2025 for model limitations.

Workflow Integration & Parameters

• Preparation: Dissolve in DMSO (≥399.3 mg/mL) or water (≥19.88 mg/mL); avoid ethanol. Use sterile technique.
• Storage: Store solid peptide desiccated at -20°C. Do not freeze/thaw repeatedly.
• Application Notes: For in vitro assays, add peptide to cell culture media at 0.1–100 nM. For in vivo rodent models, administer subcutaneously at 10–40 μg/kg/day.
• Quality Assurance: Each lot is >97.8% pure by HPLC/MS. Validate activity with cAMP or calcium flux readouts.
• Protocol Optimization: See Scenario-Driven Best Practices for sensitivity and workflow optimization advice not covered here.

Conclusion & Outlook

Parathyroid hormone (1-34) (human) is a gold-standard tool for dissecting PTH/PTHrP receptor signaling and calcium homeostasis in both bone and kidney models. Its well-characterized activity profile, lot-to-lot purity, and compatibility with advanced assembloid systems make it indispensable for translational research and protocol standardization. As kidney and bone disease models become more sophisticated, the utility of validated, high-purity peptides such as those provided by APExBIO will continue to grow. For researchers seeking to bridge basic signaling studies with preclinical models, PTH (1-34) (human) offers a reproducible, mechanistically precise platform.